Recursion Pharmaceuticals
RXRX
343 hedge funds and large institutions have $1.33B invested in Recursion Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 128 increasing their positions, 102 reducing their positions, and 40 closing their positions.
114% more capital inflows, than outflows
Capital inflows: $165M | Capital outflows: $77.3M
72% more call options, than puts
Call options by funds: $30.7M | Put options by funds: $17.8M
28% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 40
25% more repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 102
4.57% more ownership
Funds ownership: 64.41% → 68.98% (+4.6%)
2% more funds holding
Funds holding: 335 → 343 (+8)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$27.9M |
| 2 |
BlackRock
New York
|
+$23.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$20.7M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$12.8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$6.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIM
Lingotto Investment Management
London,
United Kingdom
|
-$12.2M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$10.9M |
| 3 |
Renaissance Technologies
New York
|
-$7.37M |
| 4 |
Goldman Sachs
New York
|
-$7.15M |
| 5 |
Capital Fund Management (CFM)
Paris,
France
|
-$5.86M |
RXRX Hedge Fund Activity: Q2 2026 in Review
343 of the 8,351 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q2 2026, worth a combined $1.33B — up 29% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new RXRX positions and 40 closed out — a net gain of 11 holders — while 128 added to existing stakes and 102 trimmed.
The largest buyer was Vanguard Portfolio Management, adding an estimated $27.9M. The largest seller was Lingotto Investment Management, cutting an estimated $12.2M.
- 343 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q2 2026, up from 335 in Q1 2026.
- Funds reported $1.33B of Recursion Pharmaceuticals stock for Q2 2026, up 29% quarter-over-quarter.
- 51 funds opened new Recursion Pharmaceuticals positions in Q2 2026 and 40 closed out, a net change of +11 holders.
- The largest Recursion Pharmaceuticals buyer in Q2 2026 was Vanguard Portfolio Management, an estimated $27.9M added.
- The largest Recursion Pharmaceuticals seller in Q2 2026 was Lingotto Investment Management, an estimated $12.2M sold.
Based on aggregated 13F filings for Q2 2026.